MA38146A1 - Nouveaux dérivés du benzimidazole comme antagonistes ep4 - Google Patents

Nouveaux dérivés du benzimidazole comme antagonistes ep4

Info

Publication number
MA38146A1
MA38146A1 MA38146A MA38146A MA38146A1 MA 38146 A1 MA38146 A1 MA 38146A1 MA 38146 A MA38146 A MA 38146A MA 38146 A MA38146 A MA 38146A MA 38146 A1 MA38146 A1 MA 38146A1
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
antagonists
novel benzimidazole
preparation
novel
Prior art date
Application number
MA38146A
Other languages
English (en)
Other versions
MA38146B1 (fr
Inventor
Ludwig Zorn
Laak Antonius Ter
Joachim Kuhnke
Olaf Peters
Nico Bräuer
Thorsten Blume
Jens Nagel
Stefan Kaulfuss
Gernot Langer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47325927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38146A1 publication Critical patent/MA38146A1/fr
Publication of MA38146B1 publication Critical patent/MA38146B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés du benzimidazole de la formule générale (i), des procédés pour leur préparation et leur utilisation à la préparation de produits pharmaceutiques pour le traitement d'affection et pour des indications en rapport avec le récepteur ep4.
MA38146A 2012-12-06 2013-12-03 Nouveaux dérivés du benzimidazole comme antagonistes ep4 MA38146B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195849 2012-12-06
PCT/EP2013/075309 WO2014086739A1 (fr) 2012-12-06 2013-12-03 Nouveaux dérivés du benzimidazole comme antagonistes ep4

Publications (2)

Publication Number Publication Date
MA38146A1 true MA38146A1 (fr) 2018-01-31
MA38146B1 MA38146B1 (fr) 2018-08-31

Family

ID=47325927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38146A MA38146B1 (fr) 2012-12-06 2013-12-03 Nouveaux dérivés du benzimidazole comme antagonistes ep4

Country Status (41)

Country Link
US (1) US9708311B2 (fr)
EP (1) EP2928884B1 (fr)
JP (1) JP6367822B2 (fr)
KR (1) KR20150092248A (fr)
CN (1) CN104854098B (fr)
AP (1) AP3862A (fr)
AR (1) AR093840A1 (fr)
AU (1) AU2013354226B2 (fr)
BR (1) BR112015012555B1 (fr)
CA (1) CA2893630C (fr)
CL (1) CL2015001508A1 (fr)
CR (1) CR20150296A (fr)
CU (1) CU20150056A7 (fr)
CY (1) CY1119200T1 (fr)
DK (1) DK2928884T3 (fr)
EA (1) EA028830B1 (fr)
EC (1) ECSP15022555A (fr)
ES (1) ES2637738T3 (fr)
GT (1) GT201500138A (fr)
HK (1) HK1210139A1 (fr)
HR (1) HRP20171200T1 (fr)
IL (1) IL239026A0 (fr)
JO (1) JO3431B1 (fr)
LT (1) LT2928884T (fr)
MA (1) MA38146B1 (fr)
ME (1) ME02950B (fr)
MX (1) MX2015007135A (fr)
MY (1) MY175272A (fr)
NI (1) NI201500077A (fr)
NZ (1) NZ707825A (fr)
PE (1) PE20151065A1 (fr)
PH (1) PH12015501289B1 (fr)
PL (1) PL2928884T3 (fr)
PT (1) PT2928884T (fr)
RS (1) RS56121B1 (fr)
SI (1) SI2928884T1 (fr)
TN (1) TN2015000250A1 (fr)
TW (1) TWI613198B (fr)
UA (1) UA115576C2 (fr)
UY (1) UY35177A (fr)
WO (1) WO2014086739A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US10053454B2 (en) 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
KR20160060660A (ko) 2013-10-01 2016-05-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 친화성 크로마토그래피를 위한 및 치료제의 반감기를 연장시키기 위한 화합물
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
MA39211B1 (fr) * 2013-12-24 2019-01-31 Bristol Myers Squibb Co Composés tricycliques comme agents anti-cancers
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104326937B (zh) 2014-09-03 2016-08-24 天津市肿瘤研究所 抗肿瘤化合物及其医药用途
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
WO2017173071A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018162562A1 (fr) * 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Utilisation d'un antagoniste d'ep4 pour le traitement de la douleur inflammatoire
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
KR102612649B1 (ko) 2017-05-18 2023-12-11 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
EP3625224B1 (fr) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd Dérivés d'indole n-substitués
CA3063788A1 (fr) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Derives de pyrimidine
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (fr) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methodes de traitement de la fibrose kystique
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
WO2019038156A1 (fr) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft Utilisation d'un antagoniste d'ep4 pour le traitement de l'arthrite
CA3078893A1 (fr) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Formes cristallines et compositions de modulateurs de cftr
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020014445A1 (fr) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Inhibiteurs ep4 et synthèse de ceux-ci
CN113527206B (zh) * 2020-04-17 2022-12-30 上海中泽医药科技有限公司 一种苯并氮杂环类化合物、其制备方法及用途
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
US12016847B2 (en) 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
KR102708701B1 (ko) * 2021-12-27 2024-09-24 에이치케이이노엔 주식회사 벤즈이미다졸 유도체의 제조방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1623984A (zh) 1999-12-27 2005-06-08 日本烟草产业株式会社 稠环化合物及其药物用途
DE60113809T2 (de) 2000-01-18 2006-06-22 Schering Ag Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2005533756A (ja) 2002-04-12 2005-11-10 ファイザー株式会社 Ｉｌ−６関連疾病の治療におけるｅｐ４レセプターリガンドの使用
CA2492305A1 (fr) * 2002-07-31 2004-02-05 Euro-Celtique S.A. Benzimidazoles aryle substituees et utilisation de ce compose comme bloqueurs de canal
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
AP1927A (en) 2002-11-15 2008-12-10 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
US6949564B2 (en) 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
JP5015586B2 (ja) 2003-01-29 2012-08-29 アステランド ユーケイ リミテッド Ｅｐ４受容体アンタゴニスト
NZ541544A (en) 2003-04-03 2008-06-30 Neurosearch As Benzimidazole derivatives and their use for modulating the GABAA receptor complex
TW200512147A (en) 2003-07-25 2005-04-01 Black Clawson Converting Machinery Inc Method and apparatus for splicing webs
EA009201B1 (ru) 2003-09-03 2007-12-28 Пфайзер Инк. Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2
JP2007533723A (ja) 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2565660C (fr) 2004-05-04 2009-11-03 Pfizer Inc. Composes aryl- ou heteroarylamides ortho-substitues
EA200701504A1 (ru) * 2005-01-19 2008-02-28 Биолипокс Аб Индолы, пригодные для лечения воспалений
WO2007121578A1 (fr) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Dérivés d'indolamide comme antagonistes du récepteur ep4
US7732447B2 (en) * 2006-06-22 2010-06-08 Cephalon, Inc. Fused [d]pyridazin-7-ones
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
ES2400293T3 (es) 2007-02-26 2013-04-08 Merck Canada Inc. Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
EP2185534A1 (fr) 2007-08-09 2010-05-19 Merck Sharp & Dohme Corp. Procédé pour fabriquer un dérivé de carboxamide de thiophène
CA2733247C (fr) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Derives d'amides heterocycliques en tant qu'antagonistes du recepteur ep4
WO2010117639A2 (fr) 2009-03-31 2010-10-14 The Texas A&M University System Inhibition des récepteurs de la prostaglandine e2 pour le traitement d'une endométriose
WO2010124097A2 (fr) 2009-04-22 2010-10-28 Paratek Pharmaceuticals, Inc. Composés modulateurs de facteur de transcription et leurs procédés d'utilisation
CA2789665C (fr) 2010-02-22 2020-06-16 Raqualia Pharma Inc. Utilisation d'antagonistes de recepteur ep4 dans le traitement de maladies mediees par il-23
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物

Also Published As

Publication number Publication date
CL2015001508A1 (es) 2015-07-24
EA201591087A1 (ru) 2015-12-30
RS56121B1 (sr) 2017-10-31
AP2015008463A0 (en) 2015-05-31
KR20150092248A (ko) 2015-08-12
WO2014086739A1 (fr) 2014-06-12
TWI613198B (zh) 2018-02-01
MX2015007135A (es) 2016-02-05
EP2928884B1 (fr) 2017-05-24
IL239026A0 (en) 2015-07-30
LT2928884T (lt) 2017-08-25
US9708311B2 (en) 2017-07-18
CN104854098B (zh) 2018-01-09
MA38146B1 (fr) 2018-08-31
EP2928884A1 (fr) 2015-10-14
UY35177A (es) 2014-06-30
DK2928884T3 (en) 2017-09-11
PH12015501289A1 (en) 2015-08-24
TW201422608A (zh) 2014-06-16
JO3431B1 (ar) 2019-10-20
JP2016501241A (ja) 2016-01-18
CN104854098A (zh) 2015-08-19
US20160214977A1 (en) 2016-07-28
BR112015012555A2 (pt) 2017-07-11
NI201500077A (es) 2016-02-15
NZ707825A (en) 2019-06-28
TN2015000250A1 (en) 2016-10-03
EA028830B1 (ru) 2018-01-31
PT2928884T (pt) 2017-08-25
ECSP15022555A (es) 2016-01-29
PL2928884T3 (pl) 2017-11-30
PE20151065A1 (es) 2015-08-19
UA115576C2 (uk) 2017-11-27
PH12015501289B1 (en) 2015-08-24
CU20150056A7 (es) 2015-10-27
AP3862A (en) 2016-10-31
HK1210139A1 (en) 2016-04-15
GT201500138A (es) 2017-10-05
CA2893630C (fr) 2021-02-23
AR093840A1 (es) 2015-06-24
BR112015012555B1 (pt) 2022-02-15
HRP20171200T1 (hr) 2017-12-15
CA2893630A1 (fr) 2014-06-12
MY175272A (en) 2020-06-17
CR20150296A (es) 2015-08-10
AU2013354226B2 (en) 2017-09-14
CY1119200T1 (el) 2018-02-14
JP6367822B2 (ja) 2018-08-01
ME02950B (fr) 2018-07-20
ES2637738T3 (es) 2017-10-16
AU2013354226A1 (en) 2015-06-18
SI2928884T1 (sl) 2017-09-29

Similar Documents

Publication Publication Date Title
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
CA2883210C (fr) Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA37405A1 (fr) Composés hétérocyclyle
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA32941B1 (fr) Composes organiques
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
WO2008152093A3 (fr) Diaminopyrimidines en tant que modulateurs du récepteur ep2
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA33299B1 (fr) Nouvelle formulation de naproxène
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
TN2012000563A1 (fr) Nouvelle association entre le 4(3-(cis-hexahydrocyclopenta(c)pyrrol-2(1-h)-yl)propoxy)benzamide et un antagoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent.
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant